Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis
-
Published:2019-02
Issue:1
Volume:46
Page:65-72
-
ISSN:0093-7754
-
Container-title:Seminars in Oncology
-
language:en
-
Short-container-title:Seminars in Oncology
Author:
Ciccarese ChiaraORCID,
Iacovelli RobertoORCID,
Bria EmilioORCID,
Mosillo Claudia,
Bimbatti Davide,
Fantinel Emanuela,
Bisogno Iolanda,
Brunelli Matteo,
Tortora Giampaolo
Subject
Oncology,Hematology
Reference28 articles.
1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018
2. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005
3. Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?;Dreicer;J Clin Oncol,2009
4. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma;McCaffrey;J Clin Oncol,1997
5. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis;Raggi;Ann Oncol,2016
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献